Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma – Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
